[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,652,727
  • Shares Outstanding, K 59,472
  • Annual Sales, $ 54,030 K
  • Annual Income, $ -412,780 K
  • EBIT $ -476 M
  • EBITDA $ -478 M
  • 60-Month Beta 0.58
  • Price/Sales 30.30
  • Price/Cash Flow N/A
  • Price/Book 1.48

Options Overview Details

View History
  • Implied Volatility 59.52% (+8.22%)
  • Historical Volatility 96.75%
  • IV Percentile 41%
  • IV Rank 9.70%
  • IV High 254.54% on 11/18/25
  • IV Low 38.58% on 05/21/25
  • Expected Move (DTE 4) 2.35 (8.47%)
  • Put/Call Vol Ratio 1.14
  • Today's Volume 45
  • Volume Avg (30-Day) 425
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 48,918
  • Open Int (30-Day) 46,087
  • Expected Range 25.44 to 30.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.67
  • Number of Estimates 6
  • High Estimate $-1.55
  • Low Estimate $-1.90
  • Prior Year $-1.93
  • Growth Rate Est. (year over year) +13.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.29 +14.41%
on 04/27/26
35.80 -22.37%
on 04/17/26
-5.98 (-17.71%)
since 04/08/26
3-Month
24.29 +14.41%
on 04/27/26
36.35 -23.55%
on 03/31/26
+1.26 (+4.75%)
since 02/06/26
52-Week
22.24 +24.96%
on 11/19/25
46.00 -39.59%
on 11/18/25
-0.25 (-0.89%)
since 05/08/25

Most Recent Stories

More News
Agios Pharmaceuticals: Q1 Earnings Snapshot

Agios Pharmaceuticals: Q1 Earnings Snapshot

AGIO : 27.79 (+0.94%)
Agios Reports First Quarter 2026 Financial Results and Provides Business Update

Mitapivat (PYRUKYND ® and AQVESME™) generated worldwide net revenues of $20.7 million in the first quarter of 2026, compared to $8.7 million in the first quarter of 2025 Strong initial U.S. commercial...

AGIO : 27.79 (+0.94%)
Agios Braces for Another Quarter Where the Pipeline Matters More Than the Numbers

Barchart Research What to Expect from AGIO Earnings AGIO Generated April 28, 2026 Current Price $24.80 EPS Estimate $$-1.81 Consensus Rating Moderate Buy Average Move 2.70% Agios Braces for Another Quarter...

AGIO : 27.79 (+0.94%)
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...

AGIO : 27.79 (+0.94%)
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

NEW YORK , April 1, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO) concerning...

AGIO : 27.79 (+0.94%)
AGIO ALERT- The Gross Law Firm Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money

NEW YORK , March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agios Pharmaceuticals, Inc.:

AGIO : 27.79 (+0.94%)
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Company has already submitted proposed confirmatory trial for FDA review, as required under accelerated approval pathway  Company plans to submit mitapivat sNDA in sickle cell disease in the coming...

AGIO : 27.79 (+0.94%)
AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation

NEW YORK , March 25, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO)...

AGIO : 27.79 (+0.94%)
ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK , March 18, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO)...

AGIO : 27.79 (+0.94%)
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation

NEW YORK , March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agios Pharmaceuticals, Inc.:

AGIO : 27.79 (+0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

See More

Key Turning Points

3rd Resistance Point 28.88
2nd Resistance Point 28.54
1st Resistance Point 28.17
Last Price 27.79
1st Support Level 27.46
2nd Support Level 27.12
3rd Support Level 26.75

See More

52-Week High 46.00
Fibonacci 61.8% 36.92
Fibonacci 50% 34.12
Fibonacci 38.2% 31.32
Last Price 27.79
52-Week Low 22.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.